EXTON, Pa., Feb. 13, 2018 /PRNewswire/ -- Spherix Global
Insights is a recognized market intelligence agency providing
independent coverage of the autoimmune, multiple sclerosis, and
nephrology markets. Unlike other firms offering syndicated
reports, Spherix derives actionable insights from its frequent,
commercially-focused primary market research which is highly
customized to each client's unique needs. Possessing
unrivalled content expertise and collaborating with a network of
highly engaged specialists are essential elements distinguishing
Spherix in the business analytics and intelligence space.
Oncology is a large, complex, and fast-moving market. In the
past year, multiple clients have encouraged Spherix to offer their
high value market intelligence for the oncology sector. After
careful consideration, Spherix has entered into a partnership with
several oncology experts to introduce a new quarterly series,
RealTime Dynamix: Multiple Myeloma in 2018.
Ike Nicoll and Carlton Sedberry have well-established, stellar
reputations as consultants and operators in the oncology
space. Collectively, they bring extensive expertise in
commercial assessments, market access strategy, and knowledge of
the clinical aspects in oncology. According to Sedberry,
"Biopharma companies and external stakeholders are increasingly
seeking independent and comprehensive perspectives of the
commercially relevant questions facing their products in rapidly
evolving disease states." Having spent years working with
oncologists, Nicoll added that "We see a unique opportunity to
pair our passion, knowledge, and expertise with Spherix's market
intelligence model to provide clients with an unparalleled, real
time view of the rapidly changing oncology market, and what it
means to their current and emerging products."
Over the past several months, the oncology workgroup has focused
on three foundational elements needed to launch an oncology
solution, including (1) building a representative network of
hematologists/oncologists with whom to collaborate, (2) determining
which areas of oncology merit this in-depth, frequent coverage, and
(3) working with multiple stakeholders including key opinion
leaders, biopharma commercial teams, financial analysts, and select
payers to assure that our content is comprehensive and cutting
edge.
"What we do here at Spherix is pretty unique. The passion and
commercially savvy perspectives that Ike and Carlton bring to this
space align superbly with our model," says Jennifer Robinson, President of Spherix.
"After several months of development, we are thrilled to
be launching our initial wave of independent, primary research
covering the multiple myeloma market."
RealTime Dynamix: Multiple Myeloma will explore
the evolving treatment paradigm in the US market, identify current
and potential barriers to adoption/utilization of novel agents with
current and expanding indications, and explore physicians'
perspectives on current issues and controversies in this disease
such as timing, combinations, sequencing of novel agents, the goal
of therapy and the concept of cure. Further, the study will
explore anticipated future changes, evaluate the unmet needs within
the market, and assess the commercial potential for late-stage
pipeline agents. The first report will be available in March
with a core emphasis on trends related to Amgen's Kyprolis and
Xgeva, BMS' Empliciti, Celgene's Pomalyst and Revlimid, Janssen's
Darzalex, Novartis' Farydak, and Takeda's Ninlaro and Velcade.
About Spherix Global Insights
Spherix Global Insights is an independent business intelligence and
market research company, specializing in renal, autoimmune,
neurologic and rare disease markets. Our aim is to apply our
commercial experience and unique relationships within core
specialty markets to translate data into insight, enabling our
clients to make smarter business decisions.
All company, brand or product names in this document are
trademarks of their respective holders.
For more information contact:
Email: info@spherixglobalinsights.com
www.spherixglobalinsights.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/spherix-global-insights-announces-collaboration-with-oncology-industry-experts-to-expand-portfolio-of-independent-reports-covering-highly-dynamic-markets-300598120.html
SOURCE Spherix Global Insights